Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Rang in Aktien #24658
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Aktienkurs
$3.05
Marktkapitalisierung
$58.15M
Veränderung (1 Tag)
-0.81%
Veränderung (1 Jahr)
-73.32%
Land
US
Handel Elicio Therapeutics, Inc. (ELTX)

Kategorie

Kursverlauf für Elicio Therapeutics, Inc. (ELTX)
Höchster Schlusskurs: $3.09 am 2026-08-01

Niedrigster Schlusskurs: $5.88 am 2023-11-01
Kursverlauf der Aktie von Elicio Therapeutics, Inc. von 2023 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 9.17%
2025 59.27%
2024 -21.55%
2023 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$547.71 37.80%
US
$1.04K 57.18%
NL
$145.75 455.87%
US
$118.70 -18.24%
AU
$770.19 9.84%
CH